Company Overview
IMNM Clinical-stage biotech focused on targeted cancer therapies, especially antibody–drug conjugates (ADCs) and precision oncology.
Lead Asset — Varegacestat (desmoid tumors)
Phase 3 RINGSIDE: 84% reduction in risk of progression; 56% response rate → compelling best-in-class profile.
Regulatory path: NDA planned Q2 2026, setting up the company’s first commercial launch and a major inflection point.
Pipeline Momentum (2026–2027 catalysts)
IM-1021 (ROR1 ADC): early Phase 1 data in 2026.
IM-3050 (FAP radioligand): entering Phase 1.
Multiple preclinical ADCs → INDs, broadening optionality across hard-to-treat tumors.
Why It Matters
Differentiated targets + next-gen payloads → partnerability and durable competitive moat.
Multi-asset pipeline = layered catalyst stack through 2026–2027.
Investment View
Bullish above: $21–$22
Upside target: $40–$42 — driven by NDA/launch setup and ADCs + radioligand pipeline execution.
IMNM Clinical-stage biotech focused on targeted cancer therapies, especially antibody–drug conjugates (ADCs) and precision oncology.Lead Asset — Varegacestat (desmoid tumors)
Phase 3 RINGSIDE: 84% reduction in risk of progression; 56% response rate → compelling best-in-class profile.
Regulatory path: NDA planned Q2 2026, setting up the company’s first commercial launch and a major inflection point.
Pipeline Momentum (2026–2027 catalysts)
IM-1021 (ROR1 ADC): early Phase 1 data in 2026.
IM-3050 (FAP radioligand): entering Phase 1.
Multiple preclinical ADCs → INDs, broadening optionality across hard-to-treat tumors.
Why It Matters
Differentiated targets + next-gen payloads → partnerability and durable competitive moat.
Multi-asset pipeline = layered catalyst stack through 2026–2027.
Investment View
Bullish above: $21–$22
Upside target: $40–$42 — driven by NDA/launch setup and ADCs + radioligand pipeline execution.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.